Minimal change disease associated with anti-PD1 immunotherapy: a case report

BACKGROUND: Oncologic immunotherapy is a form of therapy intended to reactivate the immune response to tumor cells using agents that modulate immune checkpoints, such as programmed cell death protein 1 and its ligand (PD-1/PD-L), and cytotoxic T-lymphocyte-associated antigen 4. Along with activation...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Bixia, Lin, Ningjing, Wang, Suxia, Wang, Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6029341/
https://www.ncbi.nlm.nih.gov/pubmed/29970032
http://dx.doi.org/10.1186/s12882-018-0958-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6029341/
https://www.ncbi.nlm.nih.gov/pubmed/29970032
http://dx.doi.org/10.1186/s12882-018-0958-6

Ejemplares similares